Katja Schulze

Technical University of Applied Sciences Wildau

Papers

2

Total Citations

66

H-Index

2

About

Dr. Katja Schulze is a translational researcher whose work bridges oncology and biotechnology, with a focus on liquid biopsy and microalgal bioengineering. Her most impactful contributions center on the use of circulating tumor DNA (ctDNA) as a dynamic biomarker in non-small cell lung cancer (NSCLC). In her highly cited 2021 study (35 citations), she demonstrated that ctDNA response during neoadjuvant atezolizumab therapy can predict surgical outcomes, offering a non-invasive tool to guide personalized immunotherapy. This work has significant implications for real-time monitoring of treatment efficacy. Earlier, Dr. Schulze made a foundational contribution to biotechnology by developing a high-throughput cultivation and screening platform for unicellular phototrophs (2014, 31 citations). This innovation enabled parallel, miniaturized processing of microalgae and cyanobacteria, accelerating research in biofuels, bioproducts, and carbon capture. By combining expertise in cancer genomics and phototrophic organism engineering, Dr. Schulze exemplifies a versatile scientist whose work impacts both clinical oncology and sustainable biotechnology. Her research continues to shape how we monitor disease and harness microbial systems for global challenges.

Research Focus

Key Achievements

2
H-Index
2
Papers
66
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC
35 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 22
🏛 Institutions: Technical University of Applied Sciences Wildau

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago